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Pancreatic secretory trypsin inhibitor in
gastrointestinal mucosa and gastric juice
T C Freeman, R J Playford, C Quinn, K Beardshall, L Poulter, J Young, J Calam
Abstract
We studied the distribution of pancreatic
secretory trypsin inhibitor (PSTI) in the
epithelia of the gastrointestinal tract and
determined whether PSTI is secreted into
gastric juice. PSTI was measured by a specific
radioimmunoassay in biopsy specimens taken
from the upper (n=8) and lower (n=7) gastro-
intestinal tract of patients with normal endo-
scopies. PSTI was present in the stomach,
small intestine, and colon. Concentrations
(1ig/g protein) were highest in the stomach,
and significantly higher in the antrum (1240,
670-1700, median and range) than in the
gastric body (370, 350-570) (p<001). Concen-
trations were similar in the duodenum (180,
80-210) and colon (160, 130-360). PSTI deter-
mined by immunohistochemistry was present
in mucus secreting gastric foveolar cells, duo-
denal Paneth cells, and colonic non mucus
cells. PSTI was present in gastric juice. The
median (range) concentration ofPSTI in basal
gastric juice from 13 patients with duodenal
ulcers was 9 (3-21) .tg/l and did not change
during stimulation with pentagastrin. The rate
of secretion, however, did increase significant-
ly (p<0c05) from 1430 (180-2810) ng/h to 4500
(1250-12 770) ng/h during pentagastrin
stimulation. PSTI was labile in acid pepsin but
stable in the neutral conditions present in the
mucus layer. The presence of pancreatic
secretory trypsin inhibitor throughout the gut
and its secretion into the lumen suggests a
hitherto unrecognised mechanism protecting
gastrointestinal epithelia against luminal
proteases.
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Pancreatic secretory trypsin inhibitor (PSTI) is a
small protein containing 56 amino acid residues
which was originally isolated from bovine pan-
creas,' and human PSTI has now been purified24
and cloned.5 PSTI is thought to protect the
pancreas from prematurely activated proteases
but the recent demonstration of PSTI-like
immunoreactivity (PSTI-LI) in other regions of
the gut"8 and its isolation from the human
stomach,9 suggests that PSTI may protect the
whole gastrointestinal tract.
The present study was undertaken to deter-
mine epithelial concentrations of PSTI using
biopsy specimens obtained from the stomach,
small intestine, and colon and to study the
cellular distribution of PSTI-LI. We also
analysed gastric juice to determine whether
PSTI is secreted into the lumen.
Methods
The local ethics committee approved the proto-
col and all patients gave informed consent.
All chemicals were purchased from BDH
(Poole, Dorset) unless otherwise stated.
PURIFICATION AND RADIOIMMUNOASSAY OF PSTI
Pancreatic juice from postoperative pancreatic
drains was stored at -20°C until extraction.
Purification ofPSTI was based on the method of
Iwai et al.'0 Briefly, pooled juice was mixed with
an equal volume of 0' 1 M sodium citrate, and the
pH adjusted to 2'5. Sodium chloride was then
added to a final concentration of 1 M and the
mixture maintained at 80°C for 40 minutes,
centrifuged at 3500 g for 45 minutes at 4°C, and
the supernatant concentrated on a C-18 Sep-Pak
cartridge (Waters Associates, Milford MA)
equilibrated with 0'05% v/v trifluoroacetic acid
in water. The cartridge was then eluted with 80%
acetonitrile in 0-05% trifluoroacetic acid, and the
eluent lyophilised. The eluent was reconstituted
in 0'05 M sodium bicarbonate and applied to a
1'5 x 100 cm column packed with Sephadex G-50
superfine (Pharmacia, Uppsala, Sweden) and
eluted with the same buffer. Fractions contain-
ing trypsin inhibitor activity were pooled,
lyophilised, and further purified by reverse
phase high pressure liquid chromatography on a
lOx 100 mm Dynamax C-8 column (12 [tm, 300
A, Rainin, Woburn MA), eluted with a gradient
of 16-30% acetonitrile in 0'1% trifluoroacetic
acid. PSTI eluted in a number of fractions as
several poorly resolved peaks and a mixture of
these fractions was used for immunisation of
rabbits. A sample was also applied to a Mono
S column (Pharmacia) equilibrated with
ammonium acetate 0'1 M, pH 3'5 and eluted
with a gradient ofammonium acetate 0 1 M, pH
3 5-4 5 (Fig 1). When the three peaks of trypsin
inhibitor that eluted from the Mono S column
were rerun on a 4-6x250 mm Dynamax C-8
reverse phase high pressure liquid chromato-
graphy column (12 tim, 150 A) eluted with a
gradient from 22-30% acetonitrile in 0'1% tri-
fluoroacetic acid, peaks I and III emerged as
single peaks whereas peak II separated into 2
peaks - III and II2. The molecular masses of the
four peaks were determined by a ZAB-SE mass
spectrometer (VG Instruments, Altrincham,
Cheshire) and the amino acid sequence ofpeak 1
was analysed by a protein sequencer (Model 470,
Applied Biosystems, Foster City, California).
Four New Zealand white rabbits were
immunised initially with 60 [ig PSTI in 0-5 ml
Freund's complete adjuvant (Sigma, Gilling-
ham, Dorset) and subsequently boosted with
30 ig PSTI in 0'5 ml Freund's incomplete
adjuvant at four weekly intervals. One produced
antiserum T4.
Human PSTI (peak III) was radioiodinated
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Figure 1: Elution profile of
pancreatic secretory t?ypsin
inhibitor (PSTI) extracted
from human pancreatic juice
from a Pharmacia Mono S
column, equilibrated with
ammonium acetate (0 I M,
pH 3 5) and eluted with a
gradient runfrompH 3 5 to
4 5. Elution ofthe PSTI
from the column was
observed as optical density at
280 nm and trypsin inhibitor
activity.
plentiful fluids. The mean (SD) weight of biopsy
specimens was 10 6 (3 0) mg.
*4*5 Biopsy specimens were immediately frozen in
liquid nitrogen where they remained until
extraction. They were extracted on ice by homo-
genisation in 200 p1 of Tris buffer (10 mM, pH
73) for 1 minute. Extracts were centrifuged at
15 850 g for 1 minute and supernatants frozen on4.0 ~4 solid CO2 and stored at -20°C before radio-
immunoassay for PSTI and measurement of
protein concentration by a modification of
Lowry's method.'2
a3.5
Fraction No
with '25I by the chloramine T method" and
tracer, 1500 cpm/tube, was incubated with anti-
serum T4 (final dilution 1:500 000) together with
PSTI standards (0-01-50 ng/ml) or samples in
1 ml ofsodium phosphate buffer (0 5 M, pH 7 3)
containing 0-15% bovine serum albumin (Sigma)
and 0 02% sodium azide. Incubation was at 4°C
for 3 days and separation was achieved by adding
to each tube at 40C, 100 pl of ethylenediamine
tetra-acetate (EDTA) (0 1 M, pH 7 3), 100 RI of
2% rabbit serum in assay buffer, 100 ptl of
second antibody (goat antirabbit antiserum, type
R 0881, Sigma) diluted 1:5 in assay buffer, and
700 p1l of 6% polyethylene glycol 6000 in
albumin free assay buffer. The tubes were mixed
and incubated at 40C for 40 minutes before being
centrifuged at 3500 g and 40C for I5 minutes.
The supernatant was aspirated into separate
tubes and both tubes counted.
COLLECTION AND EXTRACTION OF ENDOSCOPIC
BIOPSY SPECIMENS
Upper gastrointestinal biopsy specimens were
collected during routine endoscopy, using
FB25K forceps (Keymed, Southend-on-Sea,
Essex), from eight patients, three men and five
women, mean age 46 years (range 32-61 years).
These patients were under investigation for
dyspepsia, but endoscopy and other investiga-
tions proved normal and the final diagnosis was
non-ulcer dyspepsia. Paired endoscopic biopsy
specimens were normal on histological examina-
tion. No patients took any drugs within two days
ofthe examination. The mean (SD) weight of the
biopsy specimens was 6 8 (2 0) mg.
Lower gastrointestinal biopsy specimens were
collected during routine endoscopy, using
FG15L forceps (Keymed), from seven patients,
four men and three women, mean age 47 years
(range 26-65 years). These patients were under
investigation for abdominal pain or disturbance
of bowel habit, but endoscopy and other investi-
gations showed no abnormality and the final
diagnosis was the irritable bowel syndrome.
Paired endoscopic biopsy specimens were normal
on histological examination. None ofthe patients
took any drugs during the two days before
examination except for a bowel preparation,
which comprised a low residue diet, two sachets
of Picolax (Ferring, Feltham, Middx), and
GASTRIC JUICE
Gastric juice was collected during routine
pentagastrin tests on 18 patients, 13 men and five
women, in whom duodenal ulcers had been seen
at endoscopy within seven days of study. Their
mean age was 49 years (range 25-77 years). None
took any drugs in the two days before the study.
Gastric juice was collected from the last of
three 10 minute basal collections and after
stimulation with pentagastrin 0-6 rig/kg per
hour for at least 80 minutes. Juice (2 ml) was
collected directly from the aspiration tube, and
immediately neutralised by mixing with 3 ml
0-17 M sodium bicarbonate on ice. Samples were
then frozen at - 20°C before assay.
Gastric juice samples were analysed for
bilirubin with a RA-1000 analyser (Technical
Instrument Corporation), using Technicon
method, number SM-0179887. Tryptic activity
was determined by thepH stat method using Na-
p-tosyl-L-arginine methyl ester (Sigma) as sub-
strate.'3
CHROMATOGRAPHY OF GASTROINTESTINAL PSTI
PSTI-LI in gastric juice and extracts of biopsy
specimens taken from the colon and gastric
antrum were analysed by reversed phase high
pressure liquid chromatography on a 4 6x
250 mm, C-8 Dynamax column (12 lim, 150 A,
Rainin), eluted with a gradient of 16-30% aceto-
nitrile in 0 1d% triflouroacetic acid. Eluates were
lyophilised before radioimmunoassay. The
system had been previously calibrated with pan-
creatic PSTI.
STUDIES OF THE STABILITY OF PSTI IN GASTRIC
JUICE
Pentagastrin stimulated gastric juice was
obtained from two subjects with duodenal
ulcers. Tris-HCl was added to a final concentra-
tion of 10 mM, to stabilise the pH during the
study. Portions (10 ml) of each juice were
adjusted to pH 2-0, pH 4 0, pH 6-0, and pH 7*4
by the addition ofNaOH. Pure human PSTI was
then incubated with each portion at an initial
concentration of 60 ng/ml at 370C. At the times
shown in Figure 4, 250 p1 samples were
removed, immediately neutralised by addition of
an equal volume of 0- 17 M sodium bicarbonate,
frozen on solid CO2, and stored at -200C until
radioimmunoassay. In control studies PSTI was
incubated as already described, but in Tris-HCI
buffer at pH 2-0 and 4 0.
The stability of PSTI in unbuffered gastric
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Figure 2: The inhibition of
binding ofpancreatic
secretory trypsin inhibitor
(PSTI) tracer to antiserum
T4 by human PSTI and
other substances.
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juice, pH 1 2, was also tested in the presence and
absence of pepstatin (Sigma) 200 ,ug/ml with
incubation for 1 hour at 37°C.
CONCENTRATION OF PSTI IN PANCREATIC JUICE
Pancreatic juice was collected from postopera-
tive pancreatic drains from three patients (one
man, two women), two ofwhom had undergone
pancreatic surgery for pancreatic tumours and
one ofwhom had chronic pancreatitis. The juice
was frozen and stored at -20°C until the con-
centration of PSTI was determined by radio-
immunoassay.
IMMUNOHISTOCHEMISTRY
Sections 2 [tm thick were cut from samples of
normal oesophagus, stomach, and small and
large intestine. Immunoperoxidase staining
was performed using a routine peroxidase-
antiperoxidase procedure.14 Briefly, sections
were dewaxed, rehydrated, and trypsinised at
37°C for 10 minutes to unmask antigenic sites.'5
Endogenous peroxidase was blocked using
methanolic hydrogen peroxide for 30 minutes,
and the sections rinsed in phosphate buffered
saline and incubated with normal swine serum
(Dako Ltd, High Wycombe, Bucks) for 15
minutes. They were then incubated with the
primary antibody, T4, overnight at 4°C, rinsed,
and incubated with swine antirabbit immuno-
globulin (Dako) for 30 minutes at room tempera-
ture. After rinsing in phosphate buffered saline
the sections were incubated with peroxidase-
antiperoxidase complex (Dako) for 30 minutes
at the recommended dilution and rinsed again.
The sections were then developed with 3,3'-
diaminobenzidine tetrahydrochloride (Aldrich
Ltd, Gillingham, Dorset) for 5 minutes and then
counterstained lightly with haematoxylin.
Finally, the sections were dehydrated and
mounted using pertex (Histolab and Cytolab,
Hemel Hempstead, Herts). Negative controls
were obtained by substituting normal rabbit
serum for the PSTI specific antiserum.
STATISTICAL ANALYSIS
For statistical analysis Wilcoxon's rank sum test
was used and results are expressed as median and
range; p<005 was taken to be statistically
significant.
Results
PURIFICATION AND RADIOIMMUNOASSAY OF PSTI
The molecular masses of the four peaks, as
determined by mass spectrometry, were I:
6242 5, III: 6241 8, II2: 6241-6, and III: 6242 5,
compared with the predicted molecular mass
for protonated PSTI of 6242 1. Amino acid
sequence analysis of peak I showed that the N-
terminal tridecapeptide sequence of peak I was
equal to that ofhuman PSTI.
The interassay and intra-assay variabilities
of the radioimmunoassay were 17% and 8%
respectively. The detection limit of the assay was
0.05 ng/tube. The binding of tracer to antibody
was not inhibited by bovine trypsinogen
(Sigma), human epidermal growth factor
(donated by H Gregory), soybean trypsin
inhibitor (Sigma), or canine PSTI (purified by
author) (Fig 2). The ratios of cross reactivity of
the different forms to peak III were I: 0 70: 1, II:
0-86:1.
CONCENTRATIONS OF PSTI-LI IN ENDOSCOPIC
BIOPSY SPECIMENS
The concentrations of PSTI-LI in biopsy speci-
mens taken from different regions of the human
gastrointestinal tract, expressed as [tg/g wet
weight and lig/g protein in extracts, are shown in
Table I. PSTI-LI was undetectable in specimens
from the oesophagus, but the stomach contained
the most PSTI-LI, the concentration being
significantly greater in the antrum than in the
body of the stomach (p<001). Concentrations
of PSTI-LI were similar in the duodenum and
colon. There was no significant difference
between mucosal concentrations of PSTI-LI in
the first and second parts of the duodenum, or
between the regions of the colon. The median
(range) concentration for each patient was 180
(80-210) tig/g protein in the duodenum and 160(130-360) [ig/g protein in the colon.
SECRETION AND STABILITY OF PSTI-LI IN
GASTRIC JUICE
Trypsin was not detected in any sample ofgastric
juice. One sample which contained bilirubin was
excluded from analysis. PSTI-LI was,detected in
gastric juice from all patients. The concentration
TABLE I Tissue concentrations ofpancreatic secretory trypsin
inhibitor-like immunoreactivity in biopsy specimens taken
from the upper (n=8) and lower (n= 7) gastrointestinal tract
PSTI-LI/wet weight PSTI-LI/protein
(Ag/g) (Wg/g)
Region Median Range Median Range
Oesophagus <0-1 All <0 1
Stomach:
Body 19-9 11-0-40 2 370 350-570
Antrum 38 5 17-8-73-3 1240* 670-1700
Duodenum:
Firstpart 10-2 7 3-12 7 190 110-280
Second part 8-7 4-5-14-5 170 70-210
Colon:
Ascending 12-9 7-1-13-3 230 150-240
Transverse 7-7 6-5-15-7 150 90-480
Descending 7-7 5-7-13-2 150 70-360
Sigmoid 9 7 7-1-15 5 210 110-430
Rectum 10-7 6-7-12-2 170 130-290
10 100 1000 10000 100000 1000000 Statistical analysis compares tissue concentrations between the
Concentration of test substance (ng/ml) antrum and the body of the stomach. *p<0-01.
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Figure 3: Rates ofgastric
secretion ofpancreatic
secretory trypsin inhibitor
(PSTI) before and after
stimulation with
pentagastrin. The horizontal
lines indicate the medians.
*p<OOS.
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TABLE II Concentrations and secretion rates ofpancreatic
secretory trypsin inhibitor (n= 13) in basal and pentagastrin
stimulated gastric juice
Concentration of
PSTI-LI (pgll): Median Range
Basal 9 3-21
Stimulated 12 3-21
Output of
PSTI-LI (ng/h):
Basal 1430 180-2810
Stimulated 4500* 1250-12 770
* p<005 v basal.
of PSTI-LI in basal juice was not significantly
changed during stimulation with pentagastrin
(Table II). Because of the increase in the volume
of juice secreted, however, the output of PSTI-
LI rose significantly (p<005) after stimulation
with pentagastrin (Fig 3). PSTI-LI was labile in
acidic gastric juice (Fig 4). The disappearance
half times were less than 1 minute at pH 2-0, but
about 2 hours at pH 4. There was no detectable
loss of PSTI in gastric juice at pH 6-0 and 7-4 in
24 hours. There was no detectable loss of PSTI-
LI after incubation in Tris buffer at pH 2O0 and
4'0 in the absence of gastric juice for 24 hours.
After incubation of PSTI in unbuffered gastric
juice, pH 1-4 for 1 hour in the presence of
pepstatin, 81% of original immunoreactivity
remained. No PSTI-LI was detectable in the
control tube without pepstatin.
0 10 20 30 40 50
Fraction No
Figure 5: Elution ofpancreatic secretory trypsin inhibitor-like
immunoreactivity (PSTI-LI)from extracts ofcolon and
gastric antrum and gastricjuicefrom reverse phase high
performance liquid chrqmatography (Dynamax, C-8, 4-6x
250 mm, 12 tm, 150 A). The arrow indicates the elution
position ofpure PSTI.
Figure 4: Effect ofpH on the
stability ofpancreatic
secretory trypsin inhibitor-
like immunoreactivity
(PSTI-LI) in gastric juice.
The results are a mean oftwo
experiments.
._cr
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PSTI IN PANCREATIC JUICE
The median (range) concentration of PSTI in
pancreatic juice, as measured by radioimmuno-
assay, was 12 4 (8-8-16O0) mg/Il.
CHROMATOGRAPHY OF GASTROINTESTINAL PSTI-LI
PSTI-LI in gastric juice, gastric mucosa, and
colonic mucosa eluted from reversed phase high
I
performance liquid chromatography in the
characteristic position of pure pancreatic PSTI
(Fig 5).
IMMUNOHISTOCHEMISTRY
Cells containing PSTI-LI were seen in the
stomach, duodenum, and colon but not in
the oesophagus. In gastric mucosa from both
thebodyandantrum,PSTI-LIwasobservedinthe
foveolar cells lining the gastric pits (Fig 6A) but
was absent in the superficial epithelial cells. In
the duodenum intense PSTI-LI was observed in
the Paneth cells (Fig 6B) but was absent in other
cell types. In colonic mucosa the non mucus
secreting cells of the colonic crypts were positive
(Fig 6C) but the goblet cells were negative.
Discussion
In this study we determined the concentrations
of PSTI-LI for the first time in fresh tissue
obtained from the gastrointestinal tract at endo-
scopy. PSTI-LI was present in the stomach,
-E
J
C',
0
to
m
D
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Figure 6: Paraffin sections ofgastrointestinal mucosa stained with an indirect immunoperoxidase method using an anti-PSTI antibody, (A) normal gastric mucosa(original magnification x31 5, inset x 236) showingfoveolar cell positivity in gastric pits; (B) normal duodenal mucosa (original magnification x50, inset x 193)
showing Paneth cell positivity; (C) normal colonic mucosa (original magnification x31-5, inset x96) showing non mucus cell positivity in colonic crypts.
duodenum, and colon but undetectable in the
oesophagus. Tissue concentrations were greatest
in the gastric antrum. PSTI-LI was found to be
in a specific cell type in each region of the gut.
We have shown for the first time that PSTI is
secreted into the lumen of the stomach. PSTI is
rapidly destroyed by acid pepsin but stable at the
neutral pH found in the gastric mucus layer.
In a previous study Shibata et al measured
PSTI-LI in cadaveric small intestine and surgic-
ally resected stomach,6 and found concentrations
over an order of magnitude lower than in the
present study. The lower concentrations that
they reported may have been due to loss ofPSTI
through hydrolysis by' mucosal enzymes before
extraction and a higher proportion of sub-
mucosal tissues in samples.
The cellular distribution of gastrointestinal
PSTI-LI reported in the present study is con-
sistent with the main findings of two other
groups.78 The weak PSTI-LI seen by' others,
however, in the goblet cells of the colon and in
other gastric cell types, including chief cells, was
not observed in the present study.
We are not awaie of any previous report of the
secretion ofPSTI into gastric juice. The concen-
trations of PSTI-LI in gastric juice did not rise
significantly during the infusion of pentagastrin,
although there was a significant increase in the
output of gastric PSTI. Pentagastrin has been
reported to increase gastric secretion of carbo-
hydrate from the same cell type in the cat.16
In the present study PSTI was shown to be
rapidly destroyed by pepsin in gastric juice at
acid pH, but stable if the juice was neutralised.
PSTI probably exerts its protective effect in
the gastric mucus layer which is kept at a neutral
pH due to gastric secretion of bicarbonate."7
Hydrolysis of PSTI by pepsin is probably
responsible for the rapid loss of PSTI-LI in
acidic extracts of gastric mucosa that was
reported by Shibata et al.6
The results ofthe present analytical studies are
consistent with the results of others who have
shown that pancreatic PSTI exists in multiple
forms.23 These differ chiefly in the degree of
deamination ofthe asparagine residues which are
unusually abundant in PSTI. Fraction III and II2
had the predicted mass of the molecule whereas
fractions I and III had a molecular mass consist-
ent with monodeaminated PSTI. In addition,
Kikuchi et al found a form of PSTI in pancreatic
juice which had five amino acids missing from
the N-terminal, which was not found here.2
The presence of PSTI in all regions of the gut,
and its secretion into the lumen, suggest that
PSTI may protect the whole gut from proteolytic
enzymes. Gastric PSTI is presumably important
during episodes of duodenogastric reflux which
occur in health,'8 occur more frequently in some
diseases such as gastric ulcer,'9 and occur more or
less constantly after some forms of gastric
surgery.'9 Reflux of duodenal juice may raise
intragastric pH to levels at which pancreatic
enzymes are active but PSTI is stable. Concen-
trations of PSTI measured in pancreatic juice in
the present study were similar to those reported
by others3 and approximately 1000 times higher
than concentrations found in gastric juice. Con-
centrations of PSTI in the gastric mucus-
bicarbonate layer, however, may be considerably
higher than those found in the lumen of the
stomach. In addition, the concentration of tryp-
sin entering the mucus layer may be diminished
by dilution and by peptic destruction of trypsin
in the lumen of the stomach.20 It is interesting
that gastric mucosal PSTI is most abundant in
the antrum, which is most exposed to refluxed
enzymes. Colonic PSTI may protect the colonic
epithelium from pancreatic enzymes which
remain active in colonic contents.2' PSTI also
inhibits elastase and chymotrypsin4 as well as
trypsin.
Recent work has shown that PSTI is a growth
1322
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fa&u(r'J as well as a protease inhibitor. We showed
tB it hmnan PSTI stimulates growth of AR4-2J
cells derived from a rat pancreatic acinar cell
tuYolajr.72 Others have shown that human PSTI
stini-iiiat.-s growth of human fibroblasts23 and
nu^ncn 2ndthelial cells.24 The growth stimulat-
ing effect of PSTI may be a consequence of its
seqtuenlce homology with epidermal growth
factor. Rais;ed intragastric PSTI concentrations
could co-i-tribute to trophic effects seen in the
prolonged absence of gastric acid.26
Gastroirn-estinal PSTI may provide an import-
ant and hitherto unrecognised protective mecha-
nism. Fuirtqer studies are required to determine
the lactors which control the secretion of gastro-
int2stinla! PSTI and its possible role in the
conti-ol of gastrointestinal growth.
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